eNewsroom for: Advantagene Inc.

http://pressreleaseheadlines.com/wp-content/Cimy_User_Extra_Fields/Advantagene Inc.//advantagene.png

Advantagene Inc. Company Profile

Advantagene's mission is to apply biotechnology advancements to develop drugs that provide better health, better cost and better quality of life for cancer patients and their families.

News from Advantagene Inc.:

Advantagene Closes $14.2 Million in Private Placement Financing to Advance Immuno-Oncology Clinical Programs

AUBURNDALE, Mass., Sept. 12, 2016 /PRNewswire/ — Advantagene, Inc. ("Advantagene"), a clinical stage biotechnology company focused on immuno-oncology products, announced today that it has closed on a private placement of its Series A Convertible Preferred Stock resulting in gross proceeds of $14.2 million.  National Securities Corporation acted as sole placement agent for the financing.  This transaction follows […]

Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence

US-wide clinical trial for first-in-class product to begin mid-2011 AUBURNDALE, Mass., May 19, 2011 — Advantagene, Inc., a Massachusetts-based biopharmaceutical company, announced today that it reached an agreement with the U.S. Food and Drug Administration on a Special Protocol Assessment (SPA) for a pivotal Phase 3 clinical trial of ProstAtak™, its lead agent for patients […]